Cosentyx Patient Resources

Cosentyx® (secukinumab)

COSENTYX® is indicated for the treatment of:¹

• Moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.

• Active psoriatic arthritis (PsA) in adults with inadequate response to prior disease-modifying anti-rheumatic drug (DMARD) therapy, as monotherapy or in combination with methotrexate.

• Active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.

• Active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs).

• Active enthesitis-related arthritis (ERA) and active juvenile psoriatic arthritis (JPsA) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

• Moderate to severe hidradenitis suppurativa (HS; acne inversa) in adult patients with an inadequate response to conventional systemic therapy.

COSENTYX® should be initiated and supervised by a physician experienced in the diagnosis and treatment of its approved indications.

Cosentyx® Patient Information Booklets

These patient education booklets are intended to be provided to patients who have been prescribed COSENTYX® by their healthcare professional. Patients should consult their physician if they have any questions.

Cosentyx® Self-Injection Videos

These videos are intended for patients who have been prescribed Cosentyx® (secukinumab) for self-injection with a pre-filled pen by their healthcare professional, and who have received the necessary training for proper injection of the product. These videos do not replace the training that is necessary to be given by the doctor, nurse, or pharmacist.

Reference:

1. Cosentyx Prescribing Information, Singapore.